Peptide Comparison
CJC-1295 vs Tesamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two GHRHs in the same regimen: Moderate risk per peptide research literature. Same receptor: competition at pituitary GHRH receptor; no additive benefit, reduced efficiency.
Data-derived verdict
Tesamorelin has stronger documented evidence (FDA-Approved) than CJC-1295 (Anecdotal + Phase 2 (DAC)) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. CJC-1295 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: elevated igf-1; injection site reactions. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| CJC-1295 | Tesamorelin | |
|---|---|---|
| Class | GHRH analog (no-DAC or DAC forms) | GHRH analog (FDA-approved) |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life | Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion |
| Route | SC injection | SC injection |
| Half-life | No-DAC ~30 min / DAC ~8 days | ~26 min |
| Dosage (research) | No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) | 2 mg SC daily (FDA label) |
| Evidence tier | Anecdotal + Phase 2 (DAC) | FDA-Approved |
| Research depth | 57 indexed | 165 indexed |
| Availability | Compounding Restricted | Prescription |
| Reported risks | Water retention; numbness/tingling; elevated IGF-1; injection site reactions | Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CJC-1295 or Tesamorelin?
Tesamorelin has stronger documented evidence (FDA-Approved) than CJC-1295 (Anecdotal + Phase 2 (DAC)) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. CJC-1295 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between CJC-1295 and Tesamorelin?
CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); Tesamorelin is classed as GHRH analog (FDA-approved). Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; Tesamorelin, ~26 min. Routes in published studies: CJC-1295, SC injection; Tesamorelin, SC injection.
Which has stronger evidence, CJC-1295 or Tesamorelin?
Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 57 indexed studies. Tesamorelin is graded FDA-Approved, with 10 cited sources on its reference page and 165 indexed studies.
Which is more accessible, CJC-1295 or Tesamorelin?
Tesamorelin is FDA-approved and CJC-1295 is not. Catalog status: CJC-1295, Compounding Restricted; Tesamorelin, Prescription. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are CJC-1295 and Tesamorelin ever combined?
CJC-1295 and Tesamorelin appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRHs in the same regimen, moderate risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…